碳酸锂——~(131)碘——碘番酸三联疗法治疗Graves病14例临床分析

对14例 Graves 患者行碳酸锂~(131)碘—硫番酸三联疗法是放射性药物与非放射性药物联合应用的一种尝试,目的在不影响治愈率,又减少远期甲减发生率。本疗法是通过三个环节降低血 T_3、T_4水平控制甲状腺毒症。14例患者三联疗法一年结果治愈率为78.6%,有效率为100%。     

不同器官保存液对大鼠肝脏透明质酸吸收率的影响

目的　探讨不同器官保存液对大鼠肝脏透明质酸吸收率的影响 ,以评价它们对肝窦内皮细胞的保护作用。方法　大鼠肝脏原位灌洗后 ,分别在UW液、Celsior液或Histidine Tryptopan Ketoglutarate液 (HTK液 )中低温保存 16和 2 4h ,然后用含透明质酸的Kreb Henseleit液在 37℃下连续循环灌注 90min ,分别于灌注 0、15、30、6 0和 90min时检测肝脏对外源性透明质酸的吸收率。结果　低温保存 16h ,再灌注 0、15、30、6 0和 90min时 ,3种保存液保存的肝脏对外源性透明质酸的吸收率均为负值 ,表明肝窦内皮细胞受到一定程度的损伤 ,但UW液和Celsior液对肝窦内皮细胞的保护作用较HTK液为优 (P <0 .0 1) ;保存 2 4h者 ,UW液对肝窦内皮细胞的保护作用优于Celsior液和HTK液。结论　UW液对肝窦内皮细胞具有较强的保护作用     

核酸及核苷酸用于营养及免疫调节治疗的早期卫生技术评估

目的 评价核酸或核苷酸用于临床营养支持和免疫调节治疗的安全性、有效性和经济学价值。方法 检索中国生物医学文献数据库、Cochrane图书馆、MEDLINE光盘数据库、EMBASE光盘数据库,并联机检索SCI数据库,鉴定有关随机对照试验(RCTs),采用RevMan4.l进行Meta-分析。结果 纳入46个随机对照试验,涉及核酸/核苷酸用于肠内营养支持、婴儿营养、免疫调节治疗。18个研究报告了含核苷酸组分的免疫增强型肠内营养对外科术后和危重症患者预后的影响,合并分析发现免疫营养对患者感染率、住院时间和费用有肯定意义。发现1个报告在母乳代用品中加入核苷酸对婴儿免疫功能影响的研究,但报告对临床结局无明显影响。27个对“免疫核酸”用于免疫调节治疗的随机对照试验均为低质量研究,合并分析无法肯定iRNA的临床价值。结论 在外科术后患者应用免疫肠内营养制剂可降低感染率、缩短住院时间并可能减少住院费用,但不能确定作为组分之一的核苷酸的作用。尚无证据支持在母乳代用品中添加核苷酸具有临床意义。不能肯定免疫核酸是否具有免疫调节作用,亦未发现核酸在延缓衰老、改善老年人健康状况方面的可用证据。建议对核酸、核苷酸用于营养支持治疗和免疫调节治疗进行进一步研究,严格规范“核酸营养品”的宣传和应用。     

Spindle-cell glioblastoma or gliosarcoma?

'Gliosarcomas' have long been considered to be mixed gliomas and sarcomas. The present study failed to define criteria which clearly delineate 'gliosarcomas' from glioblastoma multiforme and suggests that 'gliosarcomas' should be considered as spindle cell glioblastomas. A total of six cases originally diagnosed as 'gliosarcomas' were compared with four cases of glioblastoma multiforme. No clinical or prognostic features were defined which would clearly separate 'gliosarcomas' from glioblastoma multiforme. Macroscopically, biopsies from 'gliosarcomas' ranged from firm, apparently well-circumscribed tumours to poorly circumscribed lesions with a soft consistency resembling glioblastoma multiforme. Histology revealed a continuous spectrum in which 'gliosarcomas' with large reticulin-rich areas of spindle cells merged with typical glioblastomas containing only small islands of spindle cells and reticulin staining. Immunocytochemistry for glial fibrillary acidic protein (GFAP); S100 protein and alpha-smooth muscle actin (ASMA) showed that the majority of cells in reticulin-poor areas of 'gliosarcoma' and glioblastomas expressed S100 protein and GFAP; many expressed ASMA and some expressed both GFAP and ASMA. Spindle cells in reticulin-rich areas of 'gliosarcomas' and glioblastomas most frequently expressed ASMA but many cells also expressed S100 protein and GFAP; some cells expressed both GFAP and ASMA. The results of this study and a review of the literature suggests that there is a clinical, radiological and pathological continuum with glioblastoma and 'gliosarcoma' at different ends of the spectrum. It is suggested, therefore, that most, if not all, 'gliosarcomas' be redesignated as spindle cell glioblastomas and not be considered as a mixture of glioma and sarcoma.     

The case for laparoscopic common bile duct exploration

The modern surgeon's approach to choledocholithiasis depends his or her view of cholangiography. During the early 1990 there was a swing away from cholangiography, which had previously been common practice. This was because of perceptions of difficulty with the technique, the time it took, and perhaps an implied increase in costs because of the time factor. There was no evidence on which to base this decision. This led to a marked upswing in the use of endoscopic retrograde cholangiopancreatography (ERCP). There were a large number of ERCPs with normal results performed prior to laparoscopic cholecystectomy. This paper states the case for intraoperative cholangiography and common bile duct clearance at the time of cholecystectomy. It is hoped that this technique will be adopted so patients can undergo a single procedure to remove their gallstones and common bile duct stones if they exist and to decrease the incidence of normal preoperative ERCPs and the need for a second procedure postoperatively to clear stones if they are found.     

联合检测血清透明质酸、Ⅳ型胶原及层黏蛋白对肝纤维化的诊断价值

目的 :探讨血清透明质酸 (HA)、Ⅳ型胶原 (CIV)及层黏蛋白 (LN)联合检测对肝纤维化的诊断价值。方法 :采用酶联免疫法对健康人组 2 2例、急性肝炎组 10例、慢性肝炎组 10例、肝硬化组 2 5例及慢性重症肝炎组 10例 ,分别检测血清HA ,CIV及LN的水平 ;对肝硬化组三项指标分别检测和联合检测所得的敏感性、特异性及准确性进行比较。结果 :血清中HA ,CIV及LN的水平以肝硬化组和慢性重症肝炎组最高 ,均明显高于其它组 (P <0 0 1)。肝硬化组联合检测的敏感性高于单项检测的敏感性 ,但其特异性降低。结论 :联合检测HA ,CIV及LN可提高诊断肝纤维化敏感性 ,但特异性降低 ;其中HA +CIV的敏感性和特异性较高 ,为最优联合     

旋磁场对胆结石病人胆汁中胆红素、钙、胆固醇和pH的影响

目的 探讨旋磁场与大面积静磁场对置对胆结石病人胆汁中总胆红素（BIT）、直接胆红素（BID）、间接胆红素（BII）、钙（Ca）、胆固醇（CH）和pH的影响。方法 旋磁组30例,测定旋磁处理前后65对胆汁样本。空白对照组15例,留取前后30对胆汁样本。将直径12mm圆形稀土永磁片110块,表面磁感应强度210mT,分别间隔10mm贴于210mm×220mm铁皮上形成一个大面积磁板与旋磁头表面静磁感应强度160mT,旋转平均表面磁感应强度100mT呈异名极对置,磁板置肝区背侧,旋磁头置剑突下处理40min。结果 旋磁组胆结石病人胆汁（n=65）:经旋磁场与磁板对置处理前减去处理后差值的x±s和t值分别为BIT41.81±93.52、3.59;BID 13.57±43.70、2.46;BII28.27±61.67、3.32;Ca 0.19±0.31、4.87;CH0.12±0.29、3.36;pH 0.01±0.27、0.30。除pH外,其余各项指标P值均<0.05。对照组胆汁（n=30）:间隔时间前后差值的x±s和t值分别为BIT4.42±22.05、1.14;BID2.40±12.37、1.06;BII2.52±46.27、0.30;Ca0.01±0.18、0.50;CH0.03±0.15、0.94;pH 0.009±0.06、0.84。P值均>0.05。结论 在本项磁场类型、强度和时间处理条件下,旋磁场与磁板对置能明显影响胆结石病人胆汁中的BIT、BID、BII、Ca和CH的浓度变化,且有显著降低的作用。     

维甲酸调变早幼粒白血病细胞株NB4中G-CSF及其受体表达

目的：进一步研究G－CSF在维甲酸致高白细胞症中的作用。方法：用RT－PCR、Northernblotting方法检测NB4细胞经全反式维甲酸（ATRA）作用后G－CSF mRNA表达的变化，同时用ELISA方法检测细胞培养上清液中G－CSF蛋白水平的变化；采用流式细胞技术检测NB4细胞经ATRA作用后G－CSF受体蛋白表达的变化。结果：ATRA可从基因水平上调NB4细胞中G－CSF表达，并可增加NB4细胞表面G－CSF受体的表达，G－CSF受体表达增加出现的时间虽然稍晚于G－CSF表达增加出现的时间，但仍然在较早期阶段，此时，细胞形态学和NBT实验均证实BN4细胞处于部分分化阶段。结论：在ATRA治疗APL过程中，G－CSF及其受体表达增加可能协同参与了高白细胞症的发生。     

全反式维甲酸对防治经皮冠脉介入治疗后再狭窄的临床疗效观察

目的观察不同剂量全反式维甲酸（ATRA）对防治经皮冠脉介入治疗（PCI）后再狭窄（Rs）的疗效。方法2004年7月至2005年9月连续入院行PCI的冠心病300例。随机分为全反式维甲酸正常剂量组（10mgt．i．d p．o，甲组）、强化剂量组（20mgt．i．d p．o，乙组）、对照组（丙组）。6个月后分别比较甲乙丙三组的再狭窄率、心脏事件发生率和心功能。结果300例患者中男性228例、女性72例。住院期间甲乙丙三组比较：心绞痛9％VS8％VS9％；再次急性心肌梗死（AMI）O％VS2％VS1％；再次缺血性血运重建（TVR）3％VS2％VS3％；心源性死亡4％VS6％VS4％，P〉0．05，无显著统计学差异。随访期间三组比较：心绞痛12％VS9％VS20％；再次AMII％VSO％VS1％；心源性死亡2％VS4％VS4％，P〉0．05，无显著统计学差异；再狭窄率3／33（9．1％）VS2／30（6．7％）VS12／32（37．5％）；TVR3％VS2％VS11％，P〈0．05，有显著统计学差异。结论常规剂量ATRA防治再狭窄安全有效。     

Expression of the β‐adhesin part of HRgpA in Sprague Dawley rats induces a specific antibody response

The β‐adhesin part of the Porphyromonas gingivalis W50 (ATCC 53978) protease HRgpA was cloned in an eukaryotic expression vector and expressed in COS‐7 cells. The monoclonal antibody MAb (61BG1.3), specific for the hemagglutinating domain of β‐adhesin, recognized the expressed β‐adhesin in the transfected cells both by immunoblot and immunofluorescence. Sprague Dawley rats were immunized intramuscularly with β‐adhesin encoding expression plasmid and expression plasmid without β‐adhesin insert. Skeletal muscle tissue at the site of immunization in the β‐adhesin immunized animals was shown to express this protein. The immunization induced a β‐adhesin‐specific antibody response. Sera from the immunized animals were tested for hemagglutination inhibiting activity. Due to high natural inhibiting activity in all rat sera tested, no increased hemagglutination inhibition was detected in sera from the β‐adhesin immunized animals.